Tabrecta Dosage/Direction for Use

Concise Prescribing Info Full Prescribing Info Contents Description Action Indications/Uses Dosage/Direction for Use Contraindications Special Precautions Use In Pregnancy & Lactation Adverse Reactions Drug Interactions Patient Counseling Information MIMS Class ATC Classification Regulatory Classification Presentation/Packing

Full Prescribing Info

Dosage/Direction for Use

Patient Selection: Select patients for treatment with TABRECTA based on the presence of a mutation that leads to MET exon 14 skipping in tumor specimens [see Pharmacology: Pharmacodynamics: Clinical Studies under Actions].
Recommended Dosage: The recommended dosage of TABRECTA is 400 mg orally twice daily with or without food.
Swallow TABRECTA tablets whole. Do not break, crush or chew the tablets.
If a patient misses or vomits a dose, instruct the patient not to make up the dose, but to take the next dose at its scheduled time.
Dosage Modifications for Adverse Reactions: The recommended dose reductions for the management of adverse reactions are listed in Table 2. (See Table 2.)

Click on icon to see table/diagram/image

Permanently discontinue TABRECTA in patients who are unable to tolerate 200 mg orally twice daily.
The recommended dosage modifications of TABRECTA for adverse reactions are provided in Table 3. (See Table 3.)

Click on icon to see table/diagram/image

Tabrecta Dosage/Direction for Use

capmatinib

Manufacturer:

Novartis

Distributor:

Zuellig